NCT06050369 Objective Characterizatoion of Repetitive Behaviors
| NCT ID | NCT06050369 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
| Condition | OCD |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-12-28 |
| Primary Completion | 2027-12-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2023-12-28 with a primary completion date of 2027-12-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Introduction: Repetitive behaviors (RB) constitute a broad range of symptoms across different psychiatric/neurologic disorders. The most famous are stereotypies (found in autism), compulsions (found in obsessive-compulsive-disorder, OCD) and tics (found in Gilles de la Tourette syndrome, GTS). For some patients, it is sometime difficult to distinguish the nature of the repetitive behaviors presented, however this distinction is crucial in order to chose the appropriate treatment. Aim: In our study, the investigators will try to define electrophysiological and accelerometric marker of both OCD and tics to allow objective distinction between both tics and compulsions. Method: Subjects: Both OCD and GTS patients will be recruited, 25 patients in each group. Protocol: our study protocol will involve two step: a step in laboratory, another step at patient home. * first step: both patients group will be recorded through a high density EEG and a portative EEG while doing a task of symptom provocation. Then they will get an anatomical MRI for source recontruction. Finally, the patients will have to mimic their symptom while wearing an accelerometer (a smartwatch). * second step: both patient groups will be recorded at home through a portative EEG while tagging their symptom through a smartwatch (also used for accelerometry). After the recording, the patients will keep the smartwatch for 2 weeks, still tagging their sympoms (compulsions or tics).
Eligibility Criteria
Inclusion Criteria: * To be more of 15 years old or less than 65 years old * To suffer from OCD and/or GTS (depressive, anxious and attention deficit hyperactivity disorder (ADHD) comorbidities are accepted) * To be registered to the french social security (or something equivalent) * To give written consent to participate to the research * To have contraception for women participants (or to not have any sexual activity) Exclusion Criteria: * Patients with any other psychiatric disorders than those mentioned in the inclusion criteria * Patients with any other neurological disorder than GTS * Patients who are not able to take decisions for themselves * Pregnant women * Patients not allowed to get MRI due to contraindication * Patients not speaking french
Contact & Investigator
Luc MALLET, MD
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT06050369 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 65 Years, studying OCD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06050369 currently recruiting?
Yes, NCT06050369 is actively recruiting participants. Contact the research team at luc.mallet@inserm.fr for enrollment information.
Where is the NCT06050369 trial being conducted?
This trial is being conducted at Créteil, France, Créteil, France, Paris, France.
Who is sponsoring the NCT06050369 clinical trial?
NCT06050369 is sponsored by Institut National de la Santé Et de la Recherche Médicale, France. The principal investigator is Luc MALLET, MD at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 50 participants.